Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up

被引：0

作者：

Fox, Edward ^{[1
]}

Arnold, Douglas ^{[2
]}

Cohen, Jeffrey ^{[3
]}

Coles, Alasdair ^{[4
]}

Confavreux, Christian ^{[5
]}

Hartung, Hans ^{[6
]}

Havrdova, Eva ^{[7
]}

Selmaj, Krzysztof ^{[8
]}

Weiner, Howard ^{[9
]}

Twyman, Cary ^{[10
]}

Vladic, Anton ^{[11
]}

Margolin, David ^{[12
]}

Oyuela, Pedro ^{[12
]}

Panzara, Michael ^{[12
]}

Compston, Alastair ^{[13
]}

机构：

[1] Univ Texas Med Branch, Round Rock, TX USA

[2] McGill Univ, Montreal, PQ, Canada

[3] Cleveland Clin, Solon, OH USA

[4] Addenbrookes Hosp, Cambridge, England

[5] Univ Lyon 1, F-69365 Lyon, France

[6] Univ Dusseldorf, Dusseldorf, Germany

[7] Charles Univ Prague, Sch Med 1, Prague, Czech Republic

[8] Klin J Katedra Neurol Akad, Lodz, Poland

[9] Brigham & Womens Hosp Ctr, Boston, MA USA

[10] Associates Neurol, Lexington, KY USA

[11] Sveti Duh Gen Hosp, Zagreb, Croatia

[12] Genzyme Corp, Cambridge, MA USA

[13] Univ Cambridge, Cambridge, England

来源：

NEUROLOGY | 2013年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

S41001

引用

页数：2

共 50 条

[31] Efficacy and safety of alemtuzumab in 150 patients with active relapsing-remitting MS: two-year follow-up in France
Ayrignac, X.
Collongues, N.
De Seze, J.
Vermersch, P.
Brassat, D.
Biotti, D.
Carra-Dalliere, C.
Charif, M.
Vukusic, S.
Durand-Dubief, F.
Edan, G.
Lepage, E.
Deburghgraeve, V.
Maillart, E.
Papeix, C.
Alla, P.
Berger, E.
Bourre, B.
Casez, O.
Pittion, S.
Debouverie, M.
Derache, N.
Defer, G.
Gout, O.
Deschamps, R.
Tourbah, A.
Zagnoli, F.
Ruet, A.
Ouallet, J. C.
Brochet, B.
Manchon, E.
Moreau, T.
Fromont, A.
Clavelou, P.
Guennoc, A-M.
Camdessanche, J. P.
Carpentier, A.
Coman, I.
Audoin, B.
Pelletier, J.
Magy, L.
Wiertlewski, S.
Laplaud, D.
Ciron, J.
De Broucker, T.
Frenay, C. Lebrun
Cohen, M.
Labauge, P.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 604 - 605
[32] Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
Van Wijmeersch, Bart
Singer, Barry A.
Boster, Aaron
Broadley, Simon
Fernandez, Oscar
Freedman, Mark S.
Izquierdo, Guillermo
Lycke, Jan
Pozzilli, Carlo
Sharrack, Basil
Steingo, Brian
Wiendl, Heinz
Wray, Sibyl
Ziemssen, Tjalf
Chung, Luke
Margolin, David H.
Thangavelu, Karthinathan
Vermersch, Patrick
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (13) : 1719 - 1728
[33] Lymphocyte counts and infection risk among relapsing-remitting multiple sclerosis patients treated with alemtuzumab (CARE-MS II)
Havrdova, E.
Arnold, D. L.
Cohen, J. A.
Coles, A. J.
Confavreux, C.
Fox, E. J.
Hartung, H. -P.
Selmaj, K. W.
Weiner, H. L.
Miller, T.
Twyman, C. L.
Lake, S. L.
Margolin, D. H.
Panzara, M. A.
Compston, D. A. S.
JOURNAL OF NEUROLOGY, 2013, 260 : S120 - S120
[34] Efficacy of alemtuzumab is durable over 6 years in patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy in the absence of continuous treatment (CARE-MS II)
Fox, E. J.
Alroughani, R.
Brassat, D.
Broadley, S.
Cohen, J. A.
Hartung, H. -P.
Havrdova, E.
Oreja-Guevara, C.
Selmaj, K. W.
Singer, B.
Vermersch, P.
Wray, S.
Margolin, D. H.
Thangavelu, K.
Chirieac, M.
Coles, A. J.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 596 - 597
[35] Efficacy of Alemtuzumab Is Durable Over 6 Years in Patients with Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy in the Absence of Continuous Treatment (CARE-MS II)
Broadley, S.
Alroughani, R.
Brassat, D.
Hartung, H-P
Oreja-Guevara, C.
Selmaj, K. W.
Singer, B.
Vermersch, P.
Wray, S.
Margolin, D. H.
Thangavelu, K.
Chirieac, M.
Havrdova, E.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (02) : 338 - 339
[36] Durable effect of alemtuzumab on disease activity in patients with relapsing-remitting multiple sclerosis
Wiendl, H.
Arnold, D. L.
Hupperts, R. M.
Giovannoni, G.
Margolin, D. H.
Kasten, L.
Havrdova, E.
EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 256 - 256
[37] Alemtuzumab Improves Clinical Outcomes Over 4 Years in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a: CARE-MS II Extension Study 4-Year Follow-up
Boyko, Alexey N.
Barnett, Michael
Brassat, David
Dive, Dominique
Hupperts, Raymond M. M.
Lycke, Jan
Montalban, Xavier
Sharrack, Basil
Wray, Sibyl
Margolin, David H.
Thangavelu, Karthinathan
Chirieac, Madalina
Wiendl, Heinz
NEUROLOGY, 2017, 88
[38] Alemtuzumab CARE-MS I 5-year follow-up Durable efficacy in the absence of continuous MS therapy
Havrdova, Eva
Arnold, Douglas L.
Cohen, Jeffrey A.
Hartung, Hans-Peter
Fox, Edward J.
Giovannoni, Gavin
Schippling, Sven
Selmaj, Krzysztof W.
Traboulsee, Anthony
Compston, D. Alastair S.
Margolin, David H.
Thangavelu, Karthinathan
Rodriguez, Claudio E.
Jody, Darlene
Hogan, Richard J.
Xenopoulos, Panos
Panzara, Michael A.
Coles, Alasdair J.
NEUROLOGY, 2017, 89 (11) : 1107 - 1116
[39] Immunogenicity of alemtuzumab does not impact safety and efficacy in relapsing remitting multiple sclerosis patients in the CARE-MS I study
Ziemssen, T.
Arnold, D. L.
Cohen, J. A.
Coles, A. J.
Fox, E. J.
Hartung, H. -P.
Havrdova, E.
Selmaj, K. W.
Weiner, H. L.
Palmer, J.
Margolin, D. H.
Richards, S.
Sung, C.
Panzara, M. A.
Compston, D. A. S.
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 212 - 213
[40] Alemtuzumab improves disability by month 6 independent of relapse history in relapsing-remitting multiple sclerosis patients: CARE-MS II
Fernandez, O.
Arnold, D. L.
Cohen, J. A.
Coles, A. J.
Confavreux, C.
Fox, E. J.
Hartung, H. -P.
Havrdova, E.
Selmaj, K.
Weiner, H.
Twyman, C. L.
Miller, T.
Lake, L.
Margolin, D. H.
Panzara, M. A.
JOURNAL OF NEUROLOGY, 2013, 260 : S14 - S14

← 1 2 3 4 5 →